Science Explorer Back to mapMap
Discussion
Company · Malvern · United States

PhaseBio Pharmaceuticals (United States)

Research works
10
▼ 18% vs 2018-21
Citations
215
21.9 per fractional work
Top-10% rate
3.6%
all institutions 10.0%
Open access
28%
world 40%
International
15%
world 18%

Not ranked overall: PhaseBio Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does PhaseBio Pharmaceuticals (United States) work in?

In all years, 64% of research at PhaseBio Pharmaceuticals (United States) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (64%), Biochemistry, Genetics and Molecular Biology (22%), Neuroscience (9%). It does 1.8× the world's share of Health Sciences.

Health Sciences: 6 fractional works · 64.3% of its workMedicine: 6 fractional works · 64.3% of its workCardiology and Cardiovascular Medicine: 2 fractional works · 16.9% of its workEndocrinology, Diabetes and Metabolism: 2 fractional works · 16.7% of its workSurgery: 1 fractional works · 7.4% of its workPulmonary and Respiratory Medicine: 1 fractional works · 6.0% of its workOncology: 0 fractional works · 3.5% of its workInternal Medicine: 0 fractional works · 2.6% of its workPhysiology: 0 fractional works · 2.6% of its workRheumatology: 0 fractional works · 2.2% of its workHematology: 0 fractional works · 1.6% of its workFamily Practice: 0 fractional works · 1.1% of its workGenetics: 0 fractional works · 1.1% of its workPharmacology: 0 fractional works · 1.0% of its workPsychiatry and Mental health: 0 fractional works · 0.8% of its workBiochemistry: 0 fractional works · 0.5% of its workLife Sciences: 3 fractional works · 31.9% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 21.6% of its workMolecular Biology: 1 fractional works · 15.0% of its workGenetics: 0 fractional works · 5.1% of its workBiochemistry: 0 fractional works · 1.5% of its workNeuroscience: 1 fractional works · 9.1% of its workCellular and Molecular Neuroscience: 1 fractional works · 8.5% of its workSensory Systems: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.3% of its workPharmacology: 0 fractional works · 0.8% of its workToxicology: 0 fractional works · 0.5% of its workSocial Sciences: 0 fractional works · 3.0% of its workEconomics, Econometrics and Finance: 0 fractional works · 1.8% of its workEconomics and Econometrics: 0 fractional works · 1.8% of its workBusiness, Management and Accounting: 0 fractional works · 1.1% of its workAccounting: 0 fractional works · 1.1% of its workPhysical Sciences: 0 fractional works · 0.8% of its workChemistry: 0 fractional works · 0.8% of its workOrganic Chemistry: 0 fractional works · 0.8% of its workALL ITS WORKPhaseBioPharmaceuticals…10fractional works, all years
Life Sciences32%Physical Sciences1%Health Sciences64%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 7 fields, with their numbers
    1. Medicine664.3%
    1. Biochemistry, Genetics and Molecular Biology221.6%
    2. Neuroscience19.1%
    3. Pharmacology, Toxicology and Pharmaceutics01.3%
    1. Economics, Econometrics and Finance01.8%
    2. Business, Management and Accounting01.1%
    1. Chemistry00.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at PhaseBio Pharmaceuticals (United States)?

Ranked on the quality score, Sue Arnold lead among researchers whose main affiliation is PhaseBio Pharmaceuticals (United States).

  1. 1 Sue Arnold United States · #4,213,982 worldwide 156 citations · 23 works
All ranked researchers at PhaseBio Pharmaceuticals (United States)

What are the most cited papers from PhaseBio Pharmaceuticals (United States)?

The most cited paper from PhaseBio Pharmaceuticals (United States) is "Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers" (Deepak L. Bhatt, Charles V. Pollack, Jeffrey Ian Weitz et al., 2019), with 137 citations. Next come "One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer" (129) and "Aldosterone and aldosterone synthase inhibitors in cardiorenal disease" (60).

Most cited papers
#PaperReleasedCitations
1 Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Deepak L. Bhatt, Charles V. Pollack, Jeffrey Ian Weitz et al. · New England Journal of Medicine Open access 17 Mar 2019 137
2 One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer Kelli M. Luginbuhl, Jeffrey L. Schaal, Bret R. Umstead et al. · Nature Biomedical Engineering Open access 5 Jun 2017 129
3 Aldosterone and aldosterone synthase inhibitors in cardiorenal disease Subodh Verma, Avinash Pandey, Arjun K. Pandey et al. · American Journal of Physiology-Heart and Circulatory Physiology 22 Dec 2023 60
4 Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery Deepak L. Bhatt, Charles V. Pollack, C. David Mazer et al. · NEJM Evidence 22 Dec 2021 58
5 The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists Jay M. Matthews, Na Qin, Raymond W. Colburn et al. · Bioorganic & Medicinal Chemistry Letters Open access 27 Feb 2012 37
All 15 most cited papers, with filters and sorting

Which research topics does PhaseBio Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Hormonal Regulation and Hypertension, Steroid Chemistry and Biochemistry, Antiplatelet Therapy and Cardiovascular Diseases and Coronary Interventions and Diagnostics.

  1. 1 Hormonal Regulation and Hypertension Endocrinology, Diabetes and Metabolism 1 works
  2. 2 Steroid Chemistry and Biochemistry Molecular Biology 0 works
  3. 3 Antiplatelet Therapy and Cardiovascular Diseases Cardiology and Cardiovascular Medicine 0 works
  4. 4 Coronary Interventions and Diagnostics Surgery 0 works
  5. 5 Venous Thromboembolism Diagnosis and Management Internal Medicine 0 works
  6. 6 Platelet Disorders and Treatments Hematology 0 works
  7. 7 Pharmacogenetics and Drug Metabolism Pharmacology 0 works
  8. 8 Lipoproteins and Cardiovascular Health Surgery 0 works
  9. 9 Adrenal Hormones and Disorders Endocrinology, Diabetes and Metabolism 0 works
  10. 10 Electrolyte and hormonal disorders Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available27.7%not open72.3%

World: 40% of research is openly available.

with international co-authors14.9%domestic only85.1%

World: 18% is written across borders.

How has PhaseBio Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 18% lower than in 2018-2021.

20002005201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is PhaseBio Pharmaceuticals (United States) as a percentage of every work published that year, 0.000027% in 2022.

0.000050%0.00010%PhaseBio Pharmaceuticals (United States)0.000020% in 2023200020102020

Fractional works of PhaseBio Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Malvern

All research institutions in Malvern

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about PhaseBio Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.